IP Library › Granted Patent US 12,728,152
Granted Patent B2
US 12,728,152 · App. 18/039,187 · Granted Sep 8, 2026

Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy

Inventors: Jeffrey Louis Goldberg (Menlo Park, CA); Kun-Che Chang (Redwood City, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; The United States Government as represented by the Department of Veterans Affairs
A61K38/1841A61K9/0019A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,728,152
App. No.
18/039,187
Granted
Sep 8, 2026
Kind
B2
Abstract

An effective dose of Growth Differentiation Factor 15 (GDF15) is used for prevention or treatment of proliferative vitreoretinopathy. Specifically, the disclosure provides methods and compositions for treatment of proliferative vitreoretinopathy (PVR), which is based on preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells involved in PVR.

Claims (17)

1 . A method for inhibiting or reducing the severity of proliferative vitreoretinopathy (PVR) in a human subject, the method comprising:

contacting retinal pigment epithelial cells in an eye of the human subject with a composition comprising human growth differentiation factor 15 (GDF-15) in an amount sufficient to inhibit or reduce the severity of PVR.

2 . The method of claim 1 , wherein the composition is administered intravitreally or subconjunctivally.

3 . The method of claim 1 , wherein the subject suffering from PVR has undergone rhegmatogenous retinal detachment surgery.

4 . The method of claim 1 , wherein the amount of GDF-15 sufficient to inhibit or reduce the severity of PVR reduces epithelial-mesenchymal transformation of retinal epithelial cells.

5 . The method of claim 1 , wherein said composition prevents retinal detachment in said subject.

6 . The method of claim 1 , wherein said composition reduces the formation of epiretinal membranes in said subject.

7 . The method of claim 1 , wherein said composition inhibits the contraction of retinal pigment epithelial (RPE) cells in said subject.

8 . The method of claim 1 , wherein said composition is administered every 48 hours, every 24 hours, every 12 hours, or every 6 hours.

9 . The method of claim 1 , wherein said composition is administered for 1 day, 3 days, 7 days, 14 days, 30 days, 60 days or more.

10 . The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier.

11 . The method of claim 1 , wherein the composition is administered prior to the development of PVR.

12 . The method of claim 1 , wherein the composition is administered after the development of PVR.

13 . The method of claim 1 , wherein the composition is administered following rhegmatogenous retinal detachment surgery.

14 . The method of claim 1 , wherein the amount of GDF-15 sufficient to inhibit or reduce the severity of PVR improves visual acuity.

15 . The method of claim 1 , wherein the amount of GDF-15 sufficient to inhibit or reduce the severity of PVR reduces the risk of PVR reoccurrence.

16 . The method of claim 1 , wherein the amount of GDF-15 sufficient to inhibit or reduce the severity of PVR improves the likelihood of retinal reattachment following rhegmatogenous retinal detachment surgery.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2023
From: GOLDBERG, JEFFREY LOUIS
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 064170/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2023
From: CHANG, KUN-CHE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 064259/0108 →
Continuity (2)
Provisional Application 63122789 · Dec 8, 2020
Related Publication 20240000891A1 · Jan 4, 2024
References Cited (13)
US 20180064708A1 · Kazlauskas · 2018 [cited by applicant]
US 20190284257A1 · Kumar et al. · 2019 [cited by applicant]
WO WO2021207282A2 · 2021 [cited by examiner]
Iwata_et_al_2021 (Year: 2021). [cited by examiner]
Wang_et_al_Med_Sci_Monit_March_28_2020 (Year: 2020). [cited by examiner]
Wischhusen_et_al_Front_Immunol_published_May_19_2020 (Year: 2020). [cited by examiner]
Forfar et al “Single Amino Acid Changes Impact the Ability of [cited by examiner]
Sengupta_et_al_Nucleic_Acids_Res_Nov. 2, 2018_vol. 46_No. 19_pp. 9932-9950 (Year: 2018). [cited by examiner]
Verma_et_al_2020_Tissue_Culture (Year: 2020). [cited by examiner]
Ilhan et al. (2016) “The Expression of GDF-15 in the Human Vitreous in the Presence of Retinal Pathologies with an Inflammatory Component”. Ocul Immunol Inflamm, vol. 24(2), p. 178-183. [cited by applicant]
Ishikawa et al. (2015) “Resveratrol inhibits epithelial mesenchymal transition of retinal pigment A-epithelium and development of proliferative vitreoretinopathy”. Sci Rep. vol. 5: 16386. [cited by applicant]
Idrees et al. (2019) Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin. vol. 59(1 ). 221-240. [cited by applicant]
Klaassen et al. (2017) “Identification of proteins associated with clinical and pathological features of Proliferative diabetic retinopathy in vitreous and fibrovascular membranes”. PLOS One, 011e. 2017, 1-3 vol. 12(11)… [cited by applicant]